The Burrill Report


The Burrill Report (February 7, 2011): Searching for a Faster Exit (.MP3,12.33 Mb)

The long time and high cost of drug development has investors and entrepreneurs searching for new business models that will provide them with lower risk and greater predictability. Jim Posada, founder and CEO of Resolve Therapeutics, thinks he’s got a solution. Resolve has licensed from the University of Washington a promising experimental drug to treat lupus. The plan is to take the drug into the clinic and carry it through a proof of concept study where it can be licensed to a pharmaceutical partner. Posada figures it will take about three years and $12 million to get there. With success or failure, the company’s life will essentially end at that point. We spoke to Posada about his plans for Resolve, the changes in capital markets that led to this approach, and why betting it all on a single asset may actually provide less risk than conventional company building.

February 04, 2011
http://www.burrillreport.com/article-searching_for_a_faster_exit.html